Hogstad, B.*, M.L. Berres*, R. Chakraborty, J. Tang, C. Bigenwald, M. Serasinghe, K.P.H. Lim, H. Lin, T.K. Man, R. Remark, S. Baxter, V. Kana, S. Jordan, Z. Karoulia, W.H. Kwan, M. Leboeuf, E. Brandt, H. Salmon, K. McClain, P. Poulikakos, J. Chipuk, W.J.M. Mulder, C.E. Allen, and M. Merad. 2018. RAF/MEK/extracellular signal-related kinase pathway suppresses dendritic cell migration and traps dendritic cells in Langerhans cell histiocytosis lesions. The Journal of experimental medicine 215:319-336. *equal contribution

Berres, M.L.*, J. Lehmann*, C. Jansen, J. Gortzen, C. Meyer, D. Thomas, H.W. Zimmermann, D. Kroy, F. Schumacher, C.P. Strassburg, T. Sauerbruch, C. Trautwein, H.E. Wasmuth, and J. Trebicka. 2016. Chemokine (C-X-C motif) ligand 11 levels predict survival in cirrhotic patients with transjugular intrahepatic portosystemic shunt. Liver international 36:386-394. *equal contribution

Berres, M.L.*, S. Asmacher*, J. Lehmann, C. Jansen, J. Gortzen, S. Klein, C. Meyer, H.M. Strunk, R. Fimmers, F. Tacke, C.P. Strassburg, C. Trautwein, T. Sauerbruch, H.E. Wasmuth, and J. Trebicka. 2015. CXCL9 is a prognostic marker in patients with liver cirrhosis receiving transjugular intrahepatic portosystemic shunt. Journal of hepatology 62:332-339. *equal contribution

Heinrichs, D., M.L. Berres, M. Coeuru, M. Knauel, A. Nellen, P. Fischer, C. Philippeit, R. Bucala, C. Trautwein, H.E. Wasmuth, and J. Bernhagen. 2014. Protective role of macrophage migration inhibitory factor in nonalcoholic steatohepatitis. FASEB journal 28:5136-5147.

Muller, P.A., B. Koscso, G.M. Rajani, K. Stevanovic, M.L. Berres, D. Hashimoto, A. Mortha, M. Leboeuf, X.M. Li, D. Mucida, E.R. Stanley, S. Dahan, K.G. Margolis, M.D. Gershon, M. Merad, and M. Bogunovic. 2014. Crosstalk between muscularis macrophages and enteric neurons regulates gastrointestinal motility. Cell 158:300-313.

Berres, M.L.*, K.P. Lim*, T. Peters*, J. Price, H. Takizawa, H. Salmon, J. Idoyaga, A. Ruzo, P.J. Lupo, M.J. Hicks, A. Shih, S.J. Simko, H. Abhyankar, R. Chakraborty, M. Leboeuf, M. Beltrao, S.A. Lira, K.M. Heym, V. Bigley, M. Collin, M.G. Manz, K. McClain, M. Merad, and C.E. Allen. 2014. BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups. The Journal of experimental medicine 211:669-683. *equal contribution

Berres, M.L., B. Schlosser, T. Berg, C. Trautwein, and H.E. Wasmuth. 2012. Soluble urokinase plasminogen activator receptor is associated with progressive liver fibrosis in hepatitis C infection. Journal of clinical gastroenterology 46:334-338.

Berres, M.L., C. Trautwein, M. Schmeding, D. Eurich, F. Tacke, M. Bahra, P. Neuhaus, U.P. Neumann, and H.E. Wasmuth. 2011. Serum chemokine CXC ligand 10 (CXCL10) predicts fibrosis progression after liver transplantation for hepatitis C infection. Hepatology 53:596-603.

Berres, M.L.*, R.R. Koenen*, A. Rueland, M.M. Zaldivar, D. Heinrichs, H. Sahin, P. Schmitz, K.L. Streetz, T. Berg, N. Gassler, R. Weiskirchen, A. Proudfoot, C. Weber, C. Trautwein, and H.E. Wasmuth. 2010. Antagonism of the chemokine Ccl5 ameliorates experimental liver fibrosis in mice. The Journal of clinical investigation 120:4129-4140. *equal contribution

Berres, M.L.*, S. Papen, K. Pauels*, P. Schmitz, M.M. Zaldivar, C. Hellerbrand, T. Mueller, T. Berg, R. Weiskirchen, C. Trautwein, and H.E. Wasmuth. 2009. A functional variation in CHI3L1 is associated with severity of liver fibrosis and YKL-40 serum levels in chronic hepatitis C infection. Journal of hepatology 50:370-376. *equal contribution